11/18/2024

Potassium Phosphate Injection

Products Affected - Description

- Potassium Phosphate injection, Pfizer, 3 mmol/mL, 15 mL vial, 25 count, NDC 00409-7295-01

Reason for the Shortage

- American Regent has potassium phosphate injection available.
- Amneal has potassium phosphate injection available.
- CMP Pharma has potassium phosphate injection available.
- Fresenius Kabi has potassium phosphate injection available.
- Pfizer has potassium phosphate injection on shortage due to manufacturing delays.
- Somerset has potassium phosphate injection available.

Available Products

- Potassium Phosphate injection, American Regent, 3 mmol/mL, 15 mL vial, 25 count, NDC 00517-2102-25
- Potassium Phosphate injection, American Regent, 3 mmol/mL, 5 mL vial, 25 count, NDC 00517-2051-25
- Potassium Phosphate injection, American Regent, 3 mmol/mL, 50 mL vial, 25 count, NDC 00517-2505-25
- Potassium Phosphate injection, Amneal, 3 mmol/mL, 15 mL vial, 30 count, NDC 80830-1691-02
- Potassium Phosphate injection, Amneal, 3 mmol/mL, 5 mL vial, 30 count, NDC 80830-1693-03
- Potassium Phosphate injection, Amneal, 3 mmol/mL, 50 mL vial, 15 count, NDC 80830-1692-02
- Potassium Phosphate injection, Somerset Therapeutics LLC, 3 mmol/mL, 15 mL vial, 25 count, NDC 70069-0747-25
- Potassium Phosphate injection, Somerset Therapeutics LLC, 3 mmol/mL, 5 mL vial, 25 count, NDC 70069-0746-25
- Potassium Phosphate injection, CMP Pharma, 3 mmol/mL, 15 mL vial, 10 count, NDC 46287-0024-10
- Potassium Phosphate injection, Fresenius Kabi, 3 mmol/mL, 15 mL vial, 25 count, NDC 65219-0054-29
- Potassium Phosphate injection, Fresenius Kabi, 3 mmol/mL, 5 mL vial, 25 count, NDC 65219-0052-29
- Potassium Phosphate injection, Fresenius Kabi, 3 mmol/mL, 50 mL vial, 25 count, NDC 65219-0056-29

Estimated Resupply Dates

- Pfizer has potassium phosphate 3 mmol/mL 15 mL vials on back order and the company estimates a release date of December 2027.

Safety

- FDA continues to be concerned about the risk of aluminum toxicity associated with unapproved potassium phosphate products in pediatric patients. Pfizer (Hospira) has agreed to stop distributing their unapproved product within 90 days of August 1, 2024. There are generic products that have been approved since February 2023 that have acceptable aluminum levels. More information can be found at: https://www.fda.gov/drugs/drug-safety-and-availability/infants-risk-aluminum-toxicity-unapproved-potassium-phosphates-drug-product

Updated

Updated November 18, 2024 by Michelle Wheeler, PharmD, Drug Information Specialist. Created September 1, 2021 by Michelle Wheeler, PharmD, Drug Information Specialist. © 2024, Drug Information Service, University of Utah, Salt Lake City, UT.

Disclaimer

Drug Shortage Bulletins are copyrighted by the Drug Information Service of the University of Utah and provided by ASHP as its exclusive authorized distributor. ASHP and the University of Utah make no representations or warranties, express or implied, including, but not limited to, any implied warranty of merchantability and/or fitness for a particular purpose, with respect to such information, and specifically disclaim all such warranties. Users of this information are advised that decisions regarding the use of drugs and drug therapies are complex medical decisions and that in using this information, each user must exercise his or her own independent professional judgment. Neither ASHP nor the University of Utah assumes any liability for persons administering or receiving drugs or other medical care in reliance upon this information, or otherwise in connection with this Bulletin. Neither ASHP nor the University of Utah endorses or recommends the use of any particular drug. Any application of this information for any purpose shall be limited to personal, non-commercial use.

« Back to Drug Shortage Product Bulletins

Subscribe to AHFS Clinical Drug Information to get direct access to integrated drug shortages content, plus comprehensive and actionable drug information.